{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:27:23Z","timestamp":1786944443980,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,16]]},"DOI":"10.7759\/cureus.114629","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:21:23Z","timestamp":1786944083000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico"],"prefix":"10.7759","author":[{"given":"Grecia","family":"Zavala Villafuerte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana G","family":"Perez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B","family":"Crocker Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01608-7","article-title":"Atopic dermatitis successfully treated with lebrikizumab in real-world clinical practice in Czech Republic: a case series","volume":"16","author":"Jandov\u00e1 M","year":"2026","unstructured":"Jandov\u00e1 M, Litvik R, Tich\u00fd M, Gkalpakiotis S. Atopic dermatitis successfully treated with lebrikizumab in real-world clinical practice in Czech Republic: a case series. Dermatol Ther (Heidelb). 2026, 16:669-77. 10.1007\/s13555-025-01608-7","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00793-5","article-title":"Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis","volume":"24","author":"Bernardo D","year":"2023","unstructured":"Bernardo D, Bieber T, Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2023, 24:753-64. 10.1007\/s40257-023-00793-5","journal-title":"Am J Clin Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan SM","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020, 396:345-60. 10.1016\/S0140-6736(20)31286-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index - a practical guide","volume":"33","author":"Hanifin JM","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index - a practical guide. Dermatitis. 2022, 33:187-92. 10.1097\/DER.0000000000000895","journal-title":"Dermatitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19:210-6. 10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clin Exp Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan NQ","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, et al.. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012, 92:502-7. 10.2340\/00015555-1246","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000247298","article-title":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis","volume":"186","year":"1993","unstructured":"Severity scoring of atopic dermatitis. the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993, 186:23-31. 10.1159\/000247298","journal-title":"Dermatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.303","article-title":"Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process","volume":"131","author":"Schmitt J","year":"2011","unstructured":"Schmitt J, Langan S, Stamm T, Williams HC. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol. 2011, 131:623-30. 10.1038\/jid.2010.303","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923362","article-title":"The efficacy and safety of IL-13 inhibitors in atopic dermatitis: a systematic review and meta-analysis","volume":"13","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Jing D, Cheng J, Chen X, Shen M, Liu H. The efficacy and safety of IL-13 inhibitors in atopic dermatitis: a systematic review and meta-analysis. Front Immunol. 2022, 13:923362. 10.3389\/fimmu.2022.923362","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-025-01299-9","article-title":"Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan","volume":"70","author":"Shoji J","year":"2026","unstructured":"Shoji J, Ebihara N. Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan. Jpn J Ophthalmol. 2026, 70:1-17. 10.1007\/s10384-025-01299-9","journal-title":"Jpn J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510325-real-world-clinical-outcomes-of-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-a-report-of-two-cases-from-mexico","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:21:25Z","timestamp":1786944085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510325-real-world-clinical-outcomes-of-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-a-report-of-two-cases-from-mexico"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.114629","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}